FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1921 December 25, 1997 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The study by Adachi et al. (Aug. 7 issue)¹ of intermittent etidronate therapy for the prevention of corticosteroid-induced osteoporosis addresses one of the greatest challenges in rheumatology: how to harness the benefit of the most potent antiinflammatory drug available while lessening its side effects. Unfortunately, the study has several problems.

There was a disproportionate number of patients with rheumatoid arthritis in the placebo group (21, vs. 13 in the etidronate group). Patients with this disorder are known to have an increased risk of fractures that is independent of corticosteroid therapy.² A major finding of the study was . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Millson, D., Clark, W., Dewulf, L., Batterbury, M (1999). Standards in advertising. BMJ 318: 330-330 [Full Text]